MX2022015888A - Transfección de ácido ribonucleico mensajero (arnm) de células inmunitarias. - Google Patents

Transfección de ácido ribonucleico mensajero (arnm) de células inmunitarias.

Info

Publication number
MX2022015888A
MX2022015888A MX2022015888A MX2022015888A MX2022015888A MX 2022015888 A MX2022015888 A MX 2022015888A MX 2022015888 A MX2022015888 A MX 2022015888A MX 2022015888 A MX2022015888 A MX 2022015888A MX 2022015888 A MX2022015888 A MX 2022015888A
Authority
MX
Mexico
Prior art keywords
immune cells
mrna transfection
mrna
modified
cars
Prior art date
Application number
MX2022015888A
Other languages
English (en)
Inventor
Michael Klichinsky
Yumi Yashiro-Ohtani
Kayleigh Ross
Original Assignee
Carisma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carisma Therapeutics Inc filed Critical Carisma Therapeutics Inc
Publication of MX2022015888A publication Critical patent/MX2022015888A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

La presente descripción hace referencia a métodos para modificar una célula inmunitaria mediante la administración de un ARN mensajero (ARNm) modificado que codifica un receptor de antígeno quimérico (CAR) y células inmunitarias modificadas que comprenden CAR.
MX2022015888A 2020-06-26 2021-06-25 Transfección de ácido ribonucleico mensajero (arnm) de células inmunitarias. MX2022015888A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063044855P 2020-06-26 2020-06-26
PCT/US2021/039168 WO2021263152A1 (en) 2020-06-26 2021-06-25 mRNA TRANSFECTION OF IMMUNE CELLS

Publications (1)

Publication Number Publication Date
MX2022015888A true MX2022015888A (es) 2023-03-28

Family

ID=79281947

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015888A MX2022015888A (es) 2020-06-26 2021-06-25 Transfección de ácido ribonucleico mensajero (arnm) de células inmunitarias.

Country Status (11)

Country Link
US (1) US20230235286A1 (es)
EP (1) EP4171584A1 (es)
JP (1) JP2023532280A (es)
KR (1) KR20230047086A (es)
CN (1) CN116113422A (es)
AU (1) AU2021296914A1 (es)
BR (1) BR112022026469A2 (es)
CA (1) CA3187138A1 (es)
IL (1) IL299288A (es)
MX (1) MX2022015888A (es)
WO (1) WO2021263152A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
WO2023107593A2 (en) * 2021-12-09 2023-06-15 Carisma Therapeutics Inc. In vivo delivery to immune cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2708562T3 (es) * 2013-03-14 2019-04-10 Translate Bio Inc Evaluación cuantitativa de la eficacidad de tapa de ARN mensajero
CN115537396A (zh) * 2015-03-27 2022-12-30 哈佛学院校长同事会 经过修饰的t细胞及其制备和使用方法
EP3328402A4 (en) * 2015-07-28 2019-04-03 The Trustees Of The University Of Pennsylvania CHIMERIC ANTIGEN RECEPTORS EXPRESSING MODIFIED MONOCYTES / MACROPHAGES AND USES THEREOF
AU2017350488B2 (en) * 2016-10-26 2022-06-23 Acuitas Therapeutics Inc. Lipid nanoparticle mRNA vaccines
EP3746468A4 (en) * 2018-02-02 2021-12-01 The Trustees of The University of Pennsylvania MODIFIED MONOCYTE / MACROPHAGE / DENDRITIC CELLS EXPRESSING CHIMERA ANTIGEN RECEPTORS AND USES IN DISEASES AND DISORDERS RELATED TO PROTEIN AGGREGATES
US20220119476A1 (en) * 2018-08-31 2022-04-21 The Trustees Of The University Of Pennsylvania Activation of Antigen Presenting Cells and Methods for Using the Same

Also Published As

Publication number Publication date
BR112022026469A2 (pt) 2023-03-07
EP4171584A1 (en) 2023-05-03
CA3187138A1 (en) 2021-12-30
KR20230047086A (ko) 2023-04-06
IL299288A (en) 2023-02-01
CN116113422A (zh) 2023-05-12
US20230235286A1 (en) 2023-07-27
AU2021296914A1 (en) 2023-01-19
JP2023532280A (ja) 2023-07-27
WO2021263152A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
MX2022015888A (es) Transfección de ácido ribonucleico mensajero (arnm) de células inmunitarias.
MX2019013498A (es) Receptor de antigeno quimerico y metodos para usarlo.
MX2019006438A (es) Produccion de celulas modificadas para terapia de celulas adoptivas.
MX2021005022A (es) Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
PH12018500965A1 (en) Methods and compositions for gene editing in hematopoietic stem cells
NZ612512A (en) Use of chimeric antigen receptor-modified t cells to treat cancer
GB2540694A (en) CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
BR112014006176A8 (pt) Rna transcrito in vitro ou rna sintético, composição, método para gerar uma população de células t geneticamente modificadas por rna, e, uso de uma célula t geneticamente modificada
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
AU2018397910A1 (en) Nucleic acid-containing lipid nano-particle and use thereof
NZ746914A (en) Compositions and methods for immunotherapy
EA201992469A1 (ru) Антигенспецифические иммунные эффекторные клетки
MX2014010183A (es) Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer.
MA40253A (fr) Cellules modifiées pour thérapie cellulaire adoptive
WO2019147805A3 (en) Regulatory t cells targeted with chimeric antigen receptors
EP4289944A3 (en) Method for preparing genetically-modified t cells which express chimeric antigen receptor
MX2022015062A (es) Nuevas construcciones para receptores de antígenos quiméricos.
MX2020006689A (es) Composiciones de vcar y metodos de uso.
IN2014CN02906A (es)
MX2020009463A (es) Receptor de antígeno quimérico de receptor de il-13 alfa 2 (il13ra2) para inmunoterapia de células t específica para tumor.
MX2021010670A (es) Receptores de antigeno quimerico dirigidos a cd19 y usos de los mismos en inmunoterapia.
MX2023001360A (es) Anticuerpos anti-c5 y metodos de uso.
WO2012021632A3 (en) Generation and use of pluripotent stem cells
MX2022005815A (es) Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70.
MX2020012445A (es) Receptores de antigeno quimericos con dominios enlazadores modificados y usos de los mismos.